Arrhythmia management in aging congenital heart disease patients relies on pharmacotherapy and ablation for prevalent atrial arrhythmias, while ICD recommendations for primary prevention remain unclear.
This review highlights the expanding burden of arrhythmias in aging congenital heart disease patients and summarizes current management strategies and gaps in evidence, particularly regarding primary prevention ICDs.
With the aging of congenital heart disease (CHD) patients, the burden of arrhythmias is expanding. Atrial arrhythmias, especially intra-atrial reentrant tachycardia and atrial fibrillation, are the most prevalent forms of arrhythmia. Managing comorbidities, such as obesity, using pharmacotherapy, including antiarrhythmics and anticoagulants, and ablation therapy has become the cornerstone of arrhythmia management. Ventricular tachycardias are also not rare; however, except for tetralogy of Fallot patients, recommendations for the use of implantable cardioverter defibrillators for primary prevention in other CHD patients are still not well established. Patients with CHD might also present with atrioventricular blockages because of their anatomy or following a surgical procedure. The scope of this article is to review the current knowledge and discuss the future directions regarding arrhythmia management in CHD patients.
Ntiloudi et al. (Fri,) conducted a review in Congenital Heart Disease and Arrhythmias. Arrhythmia management was evaluated. Arrhythmia management in aging congenital heart disease patients relies on pharmacotherapy and ablation for prevalent atrial arrhythmias, while ICD recommendations for primary prevention remain unclear.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: